Back to Search
Start Over
Current Scientific Rationale for the Use of Somatostatin Analogs and mTOR Inhibitors in Neuroendocrine Tumor Therapy
- Source :
- The Journal of Clinical Endocrinology & Metabolism. 97:727-737
- Publication Year :
- 2012
- Publisher :
- The Endocrine Society, 2012.
-
Abstract
- Context: Among the innovative molecules used to manage neuroendocrine tumors, there is growing interest in combining the somatostatin analogs octreotide or pasireotide (SOM230) and everolimus (RAD001), an inhibitor that targets the protein kinase mammalian target of rapamycin (mTOR). Evidence Acquisition: The aims of this review were to describe the signaling pathways targeted independently by somatostatin analogs and everolimus and to summarize the scientific rationale for the potential additive or synergistic antitumor effects of combined therapy. Evidence Synthesis: The somatostatin analogs (octreotide and lanreotide) have potent inhibitory effects on hypersecretion, thereby alleviating the symptoms associated with neuroendocrine tumors. Furthermore, the antitumor potential of octreotide is now well documented. Pasireotide, a somatostatin analog, has the advantage of targeting a wider range of somatostatin receptors (subtypes 1, 2, 3, and 5) than the analogs previously used in clinical practice (which ...
- Subjects :
- medicine.medical_specialty
Everolimus
Somatostatin receptor
Endocrinology, Diabetes and Metabolism
Biochemistry (medical)
Clinical Biochemistry
Octreotide
Context (language use)
Pharmacology
Neuroendocrine tumors
Biology
Lanreotide
medicine.disease
Biochemistry
Pasireotide
chemistry.chemical_compound
Endocrinology
Somatostatin
chemistry
Internal medicine
medicine
medicine.drug
Subjects
Details
- ISSN :
- 19457197 and 0021972X
- Volume :
- 97
- Database :
- OpenAIRE
- Journal :
- The Journal of Clinical Endocrinology & Metabolism
- Accession number :
- edsair.doi...........4a4ccbe5781fe4166070caef93b31587